insulin drugs glp 1 receptor agaonist market GLP-1 Agonist Size, Trends and Share Report 2026 Glucagon Like Peptide-1 (GLP-1) Agonists

Diabetes 10 (5), 291303

Carvalho, T

doi: 10.1152/physrev.00013.2014

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c

Importantly, large-scale randomized trials, meta-analyses, and observational studies suggest that GLP-1RAs do not significantly increase AKI risk and may even confer renal benefits in high-risk populations

This alteration of the microbiota may partly explain the variability in GLP-1RA responsiveness and presents opportunities for combination therapy using probiotics or prebiotics to augment therapeutic effectiveness